Wolfe Research downgraded MoonLake Immunotherapeutics (MLTX) to Underperform from Peer Perform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake price target lowered to $12 from $108 at Clear Street
- Jefferies downgrades MoonLake Immunotherapeutics after VELA results
- MoonLake Immunotherapeutics downgraded to Hold from Buy at Jefferies
- Morning Wrap-Up: Monday’s Biggest Stock Market Stories!
- Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news